ACXP Acurx Pharmaceuticals Inc.

4.73
-0.27  -5%
Previous Close 5
Open 4.98
52 Week Low 3.71
52 Week High 8.74
Market Cap $47,864,866
Shares 10,119,208
Float 7,814,030
Enterprise Value $48,944,998
Volume 47,442
Av. Daily Volume 77,498
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Ibezapolstat
C. difficile Infection
Phase 2b
Phase 2b
Phase 2b trial to commence early 2022.

Latest News

  1. WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.

    IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists…

    WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.

    IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

    "AWG is thrilled to be so well represented at this year's IDWeek conference," said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics and Chairman of AWG. "The COVID-19 pandemic has provided a stark reminder of the need for preparedness against emerging infectious disease threats, not the least of which includes supporting innovation of safe and effective antimicrobials for dangerous, and hard to treat, drug-resistant pathogens. Presentations from AWG member companies will highlight the latest developments in the fight against superbugs and drug resistant infections."

    For more information on AWG member company posters and participation please visit: https://antimicrobialsworkinggroup.org/idweek-2021/

    About The Antimicrobials Working Group

    AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of fourteen antimicrobials companies: Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), Cidara Therapeutics Inc. (NASDAQ:CDTX), CorMedix, Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd. (NASDAQ:ITRM), Melinta Therapeutics Inc. (NASDAQ:MLNT), Nabriva Therapeutics US Inc. (NASDAQ:NBRV), Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Qpex Biopharma, Inc., SCYNEXIS Inc. (NASDAQ:SCYX), Summit Therapeutics plc (NASDAQ:SMMT) (AIM: SUMM), UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc.

    For more information, visit: www.antimicrobialsworkinggroup.org

    About The Conafay Group

    The Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.

    For more information, visit: www.conafaygroup.com

    Media Contact: conafay@conafaygroup.com

    Cision View original content:https://www.prnewswire.com/news-releases/antimicrobials-working-group-highlights-member-company-participation-at-idweek-2021-301388427.html

    SOURCE Antimicrobials Working Group (AWG)

    View Full Article Hide Full Article
  2. STATEN ISLAND, N.Y., Sept. 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that management will participate in the A.G.P. Biotech and Specialty Pharma Conference on October 13 2021.

    The event will consist of one-on-one virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with members of Acurx Pharmaceuticals' management team should contact their A.G.P. representative.

    About Acurx Pharmaceuticals, Inc.
    Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics…

    STATEN ISLAND, N.Y., Sept. 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that management will participate in the A.G.P. Biotech and Specialty Pharma Conference on October 13 2021.

    The event will consist of one-on-one virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with members of Acurx Pharmaceuticals' management team should contact their A.G.P. representative.

    About Acurx Pharmaceuticals, Inc.

    Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

    To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

    Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements included in this press release represent our views as of September 29, 2021.   We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

    Investor Contact:

    Acurx Pharmaceuticals, Inc.

    David P. Luci, President & CEO

    Tel:  917-533-1469

    Email:  davidluci@acurxpharma.com

    Cision View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-participate-in-the-agp-biotech-and-specialty-pharma-conference-october-13-2021-301385632.html

    SOURCE Acurx Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  3. STATEN ISLAND, N.Y., Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the Infectious Disease Society of America (IDSA) IDWeekTM  2021, taking place virtually from September 29October 3, 2021:

    Title: An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective
    Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection
    Presenting Author: Professor Kevin Garey, PharmD, MS, University of Houston
    Date: Wednesday, September 29, 2021 through Sunday,

    STATEN ISLAND, N.Y., Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the Infectious Disease Society of America (IDSA) IDWeekTM  2021, taking place virtually from September 29October 3, 2021:

    Title: An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective

    Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection

    Presenting Author: Professor Kevin Garey, PharmD, MS, University of Houston

    Date: Wednesday, September 29, 2021 through Sunday, October 3, 2021

    Poster Session: Enteric Infections

    Poster Number: 701

    About Clostridioides difficile Infection (CDI). According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine). Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and a mortality rate of approximately 9.3%.

    About the Microbiome in Clostridioides difficile Infection (CDI)

    C. difficile can sometimes be a normal component of the healthy gut microbiome, but when the microbiome is thrown out of balance, the C. difficile can thrive and cause an infection. After colonization with C. difficile, the organism produces and releases the main virulence factors, the two large clostridial toxins A (TcdA) and B (TcdB). (Kachrimanidou, Microorganisms 2020, 8, 200; doi:10.3390/microorganisms8020200.) TcdA and TcdB are exotoxins that bind to human intestinal epithelial cells and are responsible for inflammation, fluid and mucous secretion, as well as damage to the intestinal mucosa.

    About the Ibezapolstat Phase 2 Clinical Trial.

    The multicenter, open-label single-arm segment of this study (Phase 2a) is to be followed by a double- blind, randomized, active-controlled segment (Phase 2b) which, together, comprise the Phase 2 clinical trial. The Phase 2 clinical trial is designed to evaluate ibezapolstat in the treatment of CDI. Phase 2a of this trial is completed and was an open-label cohort of up to 20 subjects from study centers in the United States. In this cohort, 10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days. All patients were followed for recurrence for 28± 2 days. Per protocol, after 10 patients of the projected 20 Phase 2a patients completed treatment, the Trial Oversight Committee assessed the safety and tolerability and made its recommendation regarding early termination of the Phase 2a study. Based on the recommendation of Acurx's Scientific Advisory Board (SAB) and Trial Oversight Committee, we terminated enrollment in Phase 2a early and are now advancing to Phase 2b. The SAB unanimously supported the early termination of the Phase 2a trial after 10 patients were enrolled in the trial instead of 20 patients as originally planned. The early termination was based on the evidence of meeting the primary and secondary endpoints of eliminating the infection (100%), with no recurrences of infection (100%), and with an acceptable adverse event profile. In the upcoming Phase 2b, approximately 64 additional patients with CDI will be enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI. The two treatments will be identical in appearance, dosing times, and number of capsules administered to maintain the blind. This Phase 2 clinical trial will also evaluate pharmacokinetics (PK) and microbiome changes and continue to test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance, especially overgrowth of healthy gut microbiota Actinobacteria and Firmicute phylum species during and after therapy.

    About Acurx Pharmaceuticals, Inc.

    Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

    Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements included in this press release represent our views as of September 27, 2021. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

    Investor Contact:

    Acurx Pharmaceuticals, Inc.

    David P. Luci, President & CEO

    Tel:  917-533-1469

    Email:  davidluci@acurxpharma.com

    Cision View original content:https://www.prnewswire.com/news-releases/acurx-announces-new-microbiome-data-from-its-phase-2a-clinical-trial-of-ibezapolstat-for-cdi-in-a-scientific-poster-presentation-at-idweek-2021-conference-301385126.html

    SOURCE Acurx Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  4. STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021.  

    Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

    "Inclusion in…

    STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021.  

    Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

    "Inclusion in the Russell Microcap Index reflects the ongoing achievement of our previously stated drug development objectives for our pipeline of DNA polymerase IIIC inhibitors, and the fact that, if approved, we would bring to market the first of a new class of antibiotics in over 30 years," said David P. Luci, President and CEO of Acurx. "Inclusion in the Index benefits our Company and stockholders by elevating our visibility within the global investment community. We look forward to continuing our progress towards completing the clinical development program for ibezapolstat, our lead antibiotic candidate targeting the treatment of C. difficile Infection and delivering on several key milestone catalysts through 2021 and 2022," concluded Luci.

    Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

    About FTSE Russell

    FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

    FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products, and index-based derivatives.  A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles.

    FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information on the Russell Microcap® Index and the Russell indexes reconstitution, please visit www.ftserussell.com.

    About Acurx Pharmaceuticals, Inc.

    Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).  To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

    Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements included in this press release represent our views as of August 30, 2021.   We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

    Investor Contact:

    Acurx Pharmaceuticals, Inc.

    David P. Luci, President & CEO

    Tel:  917-533-1469

    Email:  davidluci@acurxpharma.com

    Cision View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-join-the-russell-microcap-index-301368326.html

    SOURCE Acurx Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  5. STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

    Investors may listen to the presentation online beginning on September 13 at 7:00 A.M. (ET) via the link below.

    Event:

    H.C. Wainwright 23rd Annual Global Investment Conference

    Date:

    September 13-15, 2021

    Session Start Date


    and Time:

    7 a.m. ET on September 13, 2021

    Webcast:

    https://journey.ct.events/view/75943fdc-2093-4e66-a80a-c6d6e6f9ed6a

    Archived:

    90 days

    About

    STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

    Investors may listen to the presentation online beginning on September 13 at 7:00 A.M. (ET) via the link below.

    Event:

    H.C. Wainwright 23rd Annual Global Investment Conference

    Date:

    September 13-15, 2021

    Session Start Date



    and Time:

    7 a.m. ET on September 13, 2021

    Webcast:

    https://journey.ct.events/view/75943fdc-2093-4e66-a80a-c6d6e6f9ed6a

    Archived:

    90 days

    About Acurx Pharmaceuticals, Inc.

    Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

    To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

    Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements included in this press release represent our views as of August 30, 2021.   We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

    Investor Contact:

    Acurx Pharmaceuticals, Inc.

    David P. Luci, President & CEO

    Tel:  917-533-1469

    Email:  davidluci@acurxpharma.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-september-13-15-2021-301365066.html

    SOURCE Acurx Pharmaceuticals, Inc.

    View Full Article Hide Full Article
View All Acurx Pharmaceuticals Inc. News